Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Abgenix, affiliate, antidilutive, antitumor, arbitration, aware, Bachelor, biotech, Bioverativ, CCPA, Cellerant, Colby, commitment, deletion, deployment, Diantha, disruption, Doctor, Duvall, effector, eleven, extracting, figure, foreseen, freestanding, GDPR, Gilead, Gisela, guideline, Heidelberg, HIPAA, implicit, imprudent, indemnify, inflation, Inhibigenstm, inhibitory, Instruction, intercompany, irrelevant, lessor, Lincoln, LPC, lymphocyte, malware, mid, monotherapy, Nanovector, Nordic, Northeastern, Norwegian, Nouscom, opt, outsourced, phishing, prefunded, ransomware, readily, recipient, recover, recovered, reinforcing, reinfusing, remanded, retroactively, SAB, save, shipment, shrinkage, signal, social, spot, stimulation, sudden, text, thirty, thought, TIL, Topotarget, translational, transport, trend, Vaccibody, vivo
Removed:
AB, accrue, adjusting, Africa, allocate, allocation, America, amortized, antiviral, applying, arbitrary, arithmetic, attachment, attestation, auditor, authoritative, awardee, baseline, bifurcation, bill, billable, billed, book, Brazil, Bulletin, carcinoma, categorized, certainty, Checkmate, China, chlamydia, clarification, closely, CMO, Coli, commensurate, communicating, communication, comparing, computer, Contemporaneously, contingency, contingent, covenant, CRO, crucial, curve, Cytosol, daily, deciding, deducting, deep, Deliver, diluting, Diosynth, discrete, distinct, divided, division, duration, EBV, educational, embedded, emerging, Escherichia, expended, exploring, extending, field, fiscal, flat, forfeited, formed, fujifilm, fundamental, fundraising, gastric, genital, geographic, golden, greatest, headcount, Hetherington, holding, host, identification, incorporate, India, indirectly, Indonesia, induce, inhibiting, instrument, intrinsic, IPO, irrevocably, Isconova, Israel, Japan, Jonathan, Jumpstart, linked, lowest, Macrophage, maker, maximum, meant, measuring, methodology, Mexico, mimic, misleading, month, nasopharyngeal, Neon, nonbinding, Novavax, obligate, occasionally, occupied, occurred, occurring, paired, parachute, partially, past, paused, percent, Poole, predicted, prefer, prepay, principally, putative, quantity, ranging, rating, reclassified, reconciling, referenced, renewal, repaid, representation, repurchased, resale, reservation, reserve, resold, retrospectively, revalued, reviewing, Russia, salary, separated, Seth, setting, Singapore, South, spent, statistically, subjective, substance, substitute, suited, supplemental, teaching, thereunder, thousand, top, traditional, transition, travel, treated, treating, twelve, understood, unmet, unpaid, unrealized, unsecured, unused, vested, Washington, win, Zealand
Filing tables
Filing exhibits
Related press release
Associated GNCAQ transcripts
GNCAQ similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statements (Form S-3 Nos. 333-225086, 333-230577) of Genocea Biosciences, Inc. |
(2) | Registration Statements (Form S-8 Nos. 333-230062, 333-223129, 333-216183, 333-209576, 333-202333 and 333-197127) pertaining to the Amended and Restated 2014 Equity Incentive Plan of Genocea Biosciences, Inc., |
(3) | Registration Statement (Form S-8 No. 333-226655) pertaining to the Amended and Restated 2014 Equity Incentive Plan, 2014 Employee Stock Purchase Plan, as amended, and common stock issuable pursuant to Narinderjeet Singh Inducement Stock Option Agreement of Genocea Biosciences, Inc., |
(4) | Registration Statement (Form S-8 No. 333-194021) pertaining to the Amended and Restated 2007 Equity Incentive Plan and 2014 Equity Incentive Plan of Genocea Biosciences, Inc., and |
of our report dated February 13, 2020, with respect to the consolidated financial statements of Genocea Biosciences, Inc. included in this Annual Report (Form 10-K) of Genocea Biosciences, Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 13, 2020